DrugPatentWatch Database Preview
VIIBRYD Drug Profile
see a sample report or, see our see our flat-rate plans
Which patents cover Viibryd, and when can generic versions of Viibryd launch?
This drug has ninety-two patent family members in thirty-two countries.
The generic ingredient in VIIBRYD is vilazodone hydrochloride. There are fourteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the vilazodone hydrochloride profile page.
Summary for VIIBRYD
| International Patents: | 92 |
| US Patents: | 5 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 2 |
| Bulk Api Vendors: | 60 |
| Clinical Trials: | 16 |
| Patent Applications: | 35 |
| Formulation / Manufacturing: | see details |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for VIIBRYD |
| DailyMed Link: | VIIBRYD at DailyMed |
Medical Subject Heading (MeSH) Categories for VIIBRYD
Synonyms for VIIBRYD
| 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride |
| 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)piperazine hydrochloride |
| 1-[4-(5-cyanoindol-3-yl)butyl]4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride |
| 163521-08-2 |
| 2-Benzofurancarboxamide, 5-(4-(4-(5-cyano-1H-indol-3-yl)butyl)-1-piperazinyl)-, hydrochloride (1:1) |
| 2-Benzofurancarboxamide, 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]-1-piperazinyl]-, hydrochloride |
| 2794AH |
| 4-(2-carbamoyl-1-benzofuran-5-yl)-1-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-ium chloride |
| 5-(4-(4-(5-Cyano-1H-indol-3-yl)butyl)piperazin-1-yl)benzofuran-2-carboxamide hydrochloride |
| 5-(4-(4-(5-Cyano-1H-indol-3-yl)butyl)piperazin-1-yl)benzofuran-2-carboxamide monohydrochloride |
| 5-(4-[4-(5-cyano-3-indolyl)-butyl]-1-piperazinyl)-benzofuran-2carboxamide hydrochloride |
| 5-[4-[4-(5-Cyano-1H-indol-3-yl)butyl]-1-piperazinyl]-2-benzofurancarboxamide hydrochloride |
| 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]-1-benzofuran-2-carboxamide hydrochloride |
| 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]-1-benzofuran-2-carboxamide;hydrochloride |
| 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]benzofuran-2-carboxamide hydrochloride |
| 5-[4-[4-(5-Cyanoindol-3-yl)butyl]piperazin-1-yl]benzofuran-2-carboxamide hydrochloride |
| 5-{4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl}-1-benzofuran-2-carboxamide hydrochloride |
| 521V128 |
| AB0000947 |
| AC-25885 |
| AC1OCFA0 |
| AK161007 |
| AKOS024464039 |
| AN-5344 |
| API0009252 |
| AX8294006 |
| C26H27N5O2.ClH |
| CCG-213313 |
| CHEBI:70705 |
| CHEMBL1615374 |
| CS-0549 |
| D09699 |
| EBD2199528 |
| EMD 68 843 |
| EMD 68843 |
| EMD-68-843 |
| EMD-68843 |
| EMD68843 |
| HE069874 |
| HY-14261 |
| J-525160 |
| KB-81444 |
| KS-00000SKE |
| LS-34922 |
| MFCD00940014 |
| MolPort-028-744-909 |
| RL02096 |
| RL02097 |
| RPZBRGFNBNQSOP-UHFFFAOYSA-N |
| s4259 |
| SB 659746A |
| SB-659746-A |
| SB-659746A |
| SB659746-A |
| SB659746A |
| SCHEMBL867358 |
| ST24050347 |
| U8HTX2GK8J |
| UNII-U8HTX2GK8J |
| Viibryd (TN) |
| Vilazodone (Hydrochloride) |
| Vilazodone HCl |
| Vilazodone hydrochloride |
| Vilazodone hydrochloride (USAN) |
| Vilazodone hydrochloride [USAN] |
| Vilazodone Hydrochloride 1.0 mg/ml in Methanol (as free base) |
| Vilazodone hydrochloride solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material |
| Vilazodone hydrochloride, >=98% (HPLC) |
| vilazodone monohydrochloride |
| Vilazodonei |
US Patents and Regulatory Information for VIIBRYD
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergan Sales Llc | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-001 | Jan 21, 2011 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Allergan Sales Llc | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-003 | Jan 21, 2011 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Allergan Sales Llc | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-002 | Jan 21, 2011 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Allergan Sales Llc | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-001 | Jan 21, 2011 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
Paragraph IV (Patent) Challenges for VIIBRYD
| Drugname | Dosage | Strength | RLD | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 10 mg, 20 mg, and 40 mg | ➤ Subscribe | 2015-01-21 |
Non-Orange Book US Patents for VIIBRYD
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 8,921,375 | Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride | ➤ Sign Up |
| 9,624,204 | Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride | ➤ Sign Up |
| 7,381,726 | Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride | ➤ Sign Up |
| 8,927,552 | Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
see a sample report or, see our see our flat-rate plans
